Connect with us

Medical

UK’s University of Nottingham Finds Common Drug Medications Can Cause Dementia

TimesofHealth Team

Published

on

UK's University of Nottingham Finds Common Drug Medications Can Cause Dementia

A new study conducted by the United Kingdom research institution the University of Nottingham has begun to establish a direct link between a number of commonly-prescribed drugs and dementia, a debilitating age-related disease that slowly erodes neurological ability and can cause death. Though dementia’s definitive causes remain unclear and researchers have been thus-far unable to pinpoint the exact source of the disease, this study found that a group of drugs increases the likelihood of the user having dementia later in life by around 50%

The class of drugs included in the study are known as anticholinergic drugs. These drugs are responsible for relaxing the muscles, and their function can assist in a number of treatment regimens. Bladder drugs, anti-epileptic drugs, and antidepressants are considered to be anticholinergic drugs. The results of the Nottingham study should not come as a huge surprise to users who are well-acquainted with the function of these drugs, as well as the symptoms of dementia. These drugs affect the neurotransmitters in the brain, either aiding or inhibiting them in their purpose to achieve a physical or psychological end in the user.

Prolonged Usage

The study found that the drugs only increase the likelihood of contracting dementia in users that dose with the drug for around three years—every day. This means that physicians and patients should not generally worry about taking these drugs for a shorter period of time; the risk is only really present in adults that continually use the same drug over the course of several years. However, researchers will be quick to point out that, while the major effects cited in the study specifically happen at around three years, longer or shorter usage spans of the drug could still impact the user in ways that the study did not further research.

Fifty Percent

50% was the amount of increase to likelihood cited in the original study, published recently this year. The risk of contracting dementia is relatively high in the later years for most adults—and it only gets higher as the elderly man or woman continues to age. This being said, a 50% increase to the chance of getting dementia is a very significant one. According to researchers, the odds of a man or woman developing the disease at age 80 is around 1/6. This means that, if they meet the qualifications and have taken the relevant drugs for the requisite amount of time, these elderly men and woman would be looking at a 1/3 chance of developing the deadly disease.

Researchers publishing this study concluded by saying that, while doctors still must occasionally prescribe drugs like these with serious potential side effects, this knowledge should lead to a more cautious prescription of the listed drugs. Dementia is a deadly disease that almost invariably comes with a bleak prognosis. Whenever possible, physicians should try to avoid prescribing anything that could spur the onset of the terrifying and debilitating condition. More studies are expected to be published concerning these shocking findings.

Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Cannergrow: Is Cannerald a Legit Medical Cannabis Research and Production Company?

TimesofHealth Team

Published

on

Cannergrow: Is Cannerald a Legit Medical Cannabis Research and Production Company?

Switzerland-based company Canneraid founded Cannergrow, a project that focuses on professional cultivation and easy customer-end-web interface. As the platform explains on its website @ https://cannergrow.com/, it offers “the first and so far only Plant-Growing-Service in the Cannabis industry.” The company owns plants in several locations in different countries, and it operates internationally.

Cannergrow’s plant-growth solution is called Plant Sale, which it refers to as a “billion dollar market” on its website. Here are a few of the main qualities associated with Plant Sale:

  • Premium Quality Cannabis

    First, the cannabis produced by Plant Sale is of premium quality. The quality is influenced by various factors, such as lighting, ventilation, and irrigation. By managing and overseeing these qualities during the growth process, the brand works to ensure that the cannabis it produces is one of which meets quality standards.

  • Equipment at Plantations

    Second, the equipment is located at the growth plantations so that the platform can gain an advantage over other competitors. The equipment may enable processing at the location for potentially better results.

  • Digital Sales of Plants

    Third, a particularly unique quality associated with Cannergrow’s offerings is that the plants are sold digitally. As the brand explains on its website, “every digital sold plant will represent a physical space of a plant in our grow room.” The brand also subtracts running costs from the harvest and splits 50% to the company and 50% to the customer.

  • Packages

    Fourth, several packages are available. The packages are priced in euros and pricing is based upon how many grams of CBD is generated per grow. For example, 25 grams of CBD is priced at 350 EUR, while 2.5kg of CBD is valued at 35.000 EUR. Other factors that affect the harvest amount include the strain, fertilizer, watering, and other factors. Further, the harvest amount can vary from 5 to 60g.It is important to note that eth platform does make clear on its website that it does not guarantee a stable selling provider for one’s harvest of CBD.

These are just a few of the main qualities associated with Cannergrow’s plant-growth solutions. Users can also view the locations in which it grows its plants. Two of the locations are Switzerland and the United Kingdom. The Switzerland location is located 30 minutes from Bern, the minimum planned plants is 9,000, and the maximum possible plants is 18,000. The available area is 1.500m sq. On the other hand, the UK location is located in RAF Greenham Comma. The minimum planned plants is 15,000, while the maximum possible plants is 112,000. The available area is 5.200m sq.

Overall, Cannergrow is certainly a unique service and solution that businesses and individuals may want to consider for their CBD growth needs. The circumstances described above are elements that the brand uses to safeguard the quality of its plant products so that consumers can ultimately be satisfied with the plant end product. To learn more about Cannergrow and its offerings, the platform has a nifty presentation that users may want to browse through and that can be found here.

Continue Reading

Medical

Wisconsin Health Officials Warn Use of Vaping and E-Cigarettes, Tied with “Severe Lung Damage”

TimesofHealth Team

Published

on

Wisconsin Health Officials Warn Use of Vaping and E-Cigarettes, Tied with “Severe Lung Damage”

Eight teenagers have been diagnosed with severe lung damage and Wisconsin health officials trust that it may have to do with their habit of vaping reports CBD Testers.

Said findings was supposedly shared with the Wisconsin Department of Health Services (WisDHS) in early July, with uncertainty as to what might have caused it. Vaping was deemed a possibility because all of the teenagers had this habit in common.

Since being informed by the health officials, the WisDHS issued a warning indicating the effects of vaping. For the time being, the patients have been left unnamed for privacy purposes, however, the department has reassured consumers that their cases will be studied.

Here’s what the advisory was referenced saying:

“Clinicians are encouraged to remain alter for potential cases among persons presenting with progressive respiratory symptoms who report a history of inhalation drug use, particularly vaping.”

That said, all eight patients supposedly sought professional help with symptoms including coughing, fatigue, nausea and chest pain reports the news outlet.

The Chief Medical Doctor, Michael Gutzeit, attending all eight causes is aware of the popularity with such activities, especially in younger kids. However, he reminded consumers that the dangers associated with vaping are still unknown even if this is deemed a safer alternative to smoking.

“We don’t have a lot of information about the long-term effects or even the short-term effects. What we do know is vaping is dangerous. It’s especially dangerous in teenagers and young adults,” said Gutzeit, none of which have been stated with scientific evidence.

Continue Reading

Cannabis

Cannabis’ Pain-Relieving Property Revealed, Flavonoids Cannflavin A and Cannflavin B: New Study

TimesofHealth Team

Published

on

Cannabis’ Pain-Relieving Property Revealed, Flavonoids Cannflavin A and Cannflavin B: New Study

Researchers at Ontario’s University of Guelph allegedly found the answer to what permits cannabis to offer pain-relieving benefits reports Ganjapreneur. According to the team, who announced their findings on Wednesday, July 24, the plant carries an array of

“Pain-relieving molecules that are 30 times more powerful at reducing inflammation than Aspirin.”

In particular, the key players that make a difference are two types of flavonoids, including cannflavin A and cannflavin B, both of which are deemed free of mind-altering effects.

Co-authors, Professor Tariq Akhtar and Professor Steven Rothstein from the university’s Molecular and Cellular Biology department elaborated on what was witnessed.

The former argued that the molecules were capable of targeting the inflammation “at the source,” while the latter noted that the flavonoids are at rather low levels. Rothstein further argued that due to its low content, “it’s not feasible” to create plants to carry more of it.

This project has supposedly led to the involvement of Toronto-based, Anahit International Corp.’s involvement in which a patent has been licensed from the university to biosynthesize the plant’s source of flavonoids.

COO of Anahit International Corp, Darren Carrigan shared that more products including said compound will be offered. In particular, Carrigan anticipates

“a variety of medical and athletic products such as creams, pills, sports drinks, transdermal patches and other innovative options.”

Continue Reading
Advertisement

Trending